The Program Team Leader (PTL) is responsible for leading a cross-functional matrix team to bring a candidate compound (PRX003) in Prothena’s portfolio through registration, commercialization, and life-cycle management. The PTL leads the Program Team (PT) in the creation and management of the Target Product Profile and the development and execution of a cross-functional compound development strategy throughout the lifecycle of the asset. The PTL is the champion of the product at all levels across the Prothena organization and is responsible for the cross-functional integration of asset related functional strategies and execution plans. The PTL is also responsible for communicating progress against the development plans and for obtaining guidance and approval of program parameters from Prothena’s Leadership team and other governance bodies, as appropriate.
This position reports to the Vice President Portfolio Management.
PRX003 is an investigational monoclonal antibody that targets CD146, also known as melanoma cell adhesion molecule (MCAM), for the potential treatment of inflammatory diseases, such as psoriasis and psoriatic arthritis.
CD146 is a cell adhesion molecule expressed on the surface of Th17 cells which are an underlying cause of several inflammatory diseases. CD146 functions like hook-and-loop fasteners, allowing Th17 cells to adhere to the blood vessel wall and migrate into tissues to initiate the inflammatory process.
PRX003 is designed to occupy CD146, leading to downregulation which sequesters pro-inflammatory Th17 cells in the bloodstream and prevents their migration into tissue. PRX003 may also induce the demargination of Th17 cells that are already adherent to blood vessels and/or tissue.
Prothena announced its strategy to advance a Phase 2 clinical study of PRX003 in patients with psoriatic arthritis based on certain pre-specified criteria being met in an ongoing Phase 1b proof-of biology study in patients with psoriasis.
Education and/or Experience:
Competencies and Attributes: